載脂蛋白E(APOE)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Apolipoprotein E (APOE)
Apo-E; AD2; Apoprotein; Alzheimer Disease 2(E4-Associated,Late Onset
- 編號(hào)CEA704Rb
- 物種Oryctolagus cuniculus (Rabbit，兔)相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法競爭抑制
- 反應(yīng)時(shí)長2h
- 檢測范圍493.8-40,000pg/mL
- 靈敏度最小可檢測劑量小于等于182.5pg/mL.
- 樣本類型Serum, plasma and other biological fluids
- 下載英文說明書 中文說明書
- 規(guī)格48T96T96T*596T*1096T*100
- 價(jià)格¥ 2873¥ 4104¥ 18468¥ 34884¥ 287280
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
實(shí)驗(yàn)結(jié)果圖
標(biāo)準(zhǔn)曲線圖
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測載脂蛋白E(APOE)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的載脂蛋白E(APOE)（加標(biāo)樣品），重復(fù)測定并計(jì)算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 79-101 | 83 |
| EDTA plasma(n=5) | 81-90 | 86 |
| heparin plasma(n=5) | 86-101 | 97 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測定，每個(gè)樣本使用同一試劑盒重復(fù)測定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的載脂蛋白E(APOE)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中載脂蛋白E(APOE)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 86-93% | 78-101% | 82-102% | 96-104% |
| EDTA plasma(n=5) | 89-96% | 99-105% | 80-104% | 90-97% |
| heparin plasma(n=5) | 89-103% | 90-97% | 90-101% | 81-89% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）50µL，
加入50µL檢測液A(臨用前配制);
37°C溫育1小時(shí)。
3. 洗板3次；
4. 加檢測溶液B100µL，37°C孵育30分鐘；
5. 洗板5次；
6. 加TMB底物90µL，37°C孵育10-20分鐘；
7. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
本試劑盒應(yīng)用競爭抑制酶聯(lián)免疫分析法測定標(biāo)本中待測物質(zhì)水平。將載脂蛋白E(APOE)單克隆抗體包被微孔板，制成固相載 體，往包被抗體的微孔中同時(shí)加入生物素標(biāo)記的抗原和待測抗原(標(biāo)準(zhǔn)品或樣本)，待測抗原與生物素標(biāo)記抗原對(duì)特異性抗體進(jìn)行競爭結(jié)合。溫育后經(jīng)洗滌去掉未結(jié)合物，然后加入HRP標(biāo)記的親和素，經(jīng)過溫育和徹底洗滌后加入底物TMB顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。待測標(biāo)本濃度越高，標(biāo)記抗原和抗體的結(jié)合就越受到抑制，顯色愈淺。顯色的深淺與酶量呈正相關(guān)，而與樣品中待測物質(zhì)含量呈負(fù)相關(guān)。用酶標(biāo)儀在450nm波長下測定吸光度（O.D.值），計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Oryctolagus cuniculus (Rabbit，兔) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA704Rb01 | 載脂蛋白E(APOE)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA704Rb51 | 載脂蛋白E(APOE)多克隆抗體 | WB; IHC; ICC; IP. |
| MAA704Rb21 | 載脂蛋白E(APOE)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA704Rb | 載脂蛋白E(APOE)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| CEA704Rb | 載脂蛋白E(APOE)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA704Rb | 載脂蛋白E(APOE)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Seizure - European Journal of Epilepsy | Cerebrospinal fluid apolipoprotein E concentration decreases after seizure[Seizure: PIIS1059131109002441] |
| Biochimica et Biophysica Acta | Hepatic lipase- and endothelial lipase-deficiency in mice promotes macrophage-to-feces RCT and HDL antioxidant properties[PubMed: 23328279 ] |
| Medical Oncology | Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma[Pubmed: 23609192] |
| Diabetes. | Adipocyte Atp-Binding Cassette G1 Promotes Triglyceride Storage, Fat Mass Growth And Human Obesity[Pubmed:25249572] |
| renal failure | Frequencies of apolipoprotein E alleles in depressed patients undergoing hemodialysis – a case-control study[PubMed: 25707516] |
| Biochim Biophys Acta | Culturing of HepG2 cells with human serum improve their functionality and suitability in studies of lipid metabolism[PubMed: 26515253] |
| Diabetes | Adipocyte ATP-binding cassette G1 promotes triglyceride storage, fat mass growth, and human obesity[PubMed: 25249572] |
| Scientific Reports | Adaptive?immunity?against?gut?microbiota?enhances?apoE-mediated?immune?regulation?andreduces?atherosclerosis?and?western-diet-related?inflammation.[pubmed:27383250] |
| Biochemical Pharmacology? | Differential effects of apoE and apoJ mimetic peptides on the action of an anti-Aβ scFv in 3xTg-AD mice[Pubmed:30026023] |
| Oncotarget | Deletion of plasma Phospholipid Transfer Protein (PLTP) increases microglial phagocytosis and reduces cerebral amyloid-β deposition in the J20 mouse?…[Pubmed:29731975] |
| Proteomics Clinical Applications | Comparative proteomics analysis of serum proteins in gestational diabetes during early and middle stages of pregnancy[Pubmed: 31162828] |
| Nature Communications | Hepatic HuR modulates lipid homeostasis in response to high-fat diet[Pubmed: 32546794] |
| VETERINARY PATHOLOGY | Pathology and Proteomics-Based Diagnosis of Localized Light-Chain Amyloidosis in Dogs and Cats[Pubmed: 32880234] |
| Journal of Clinical Medicine | The Significance of Apolipoprotein E Measurement in the Screening of Fetal Down Syndrome[33321701] |
| Cancer Cell Int | Discovery and validation of FBLN1 and ANT3 as potential biomarkers for early detection of cervical cancer[33602229] |
| Nat Commun | GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity[34853313] |
| Talanta | Iridium nanoclusters as high sensitive-tunable elemental labels for immunoassays: Determination of IgE and APOE in aqueous humor by inductively coupled?…[Pubmed:35378356] |
| Analytica Chimica Acta | Gold nanoclusters as elemental label for the sequential quantification of apolipoprotein E and metallothionein 2A in individual human cells of the retinal?…[Pubmed:35361429] |
